US SEC Trading Suspension Halt Orders — June 23, 2026

Self-reported equity award violation to Nasdaq on March 27, 2026, received only a reprimand (not delisting), demonstrating proactive governance and shareholder ratification reducing regulatory risk

Received delisting determination on June 22, 2026, for minimum bid price ($1.00) and net income rule non-compliance, with suspension effective June 24, 2026—shares will move to Pink Limited Market, a material negative catalyst

Delisting triggers immediate liquidity crisis—no insider buying or forward guidance filed to support investor confidence, creating a 'show cause' risk for further price erosion

Nasdaq deemed the violations 'not deliberate' and closed the matter with no further action, indicating the company can maintain its listed status and continue trading without overhang

Company intends to appeal to the Nasdaq Listing and Hearing Review Council, but the appeal will NOT stay the suspension, creating a binary event risk with no interim trading support

Expected to trade on Pink Limited Market under the same symbol—transition to OTC markets historically leads to wider bid-ask spreads, lower volumes, and potential further price declines (30-50% typical)

Rescinded recent equity grants to officers and directors as part of corrective action, eliminating potential governance dilution concerns and aligning management with shareholders

If no buyer emerges in OTC markets, the stock may face a 'penny stock' designation and additional regulatory burdens under SEC Rule 15g-9, making it harder for retail investors to trade

Corrective measures (self-report, ratification, rescission) were resolved within ~3 months, demonstrating effective crisis management—a positive signal for corporate governance

No insider activity (buys/sells/pledges) filed post-delisting notice, suggesting management has not signaled confidence with personal capital—a bearish signal for retail holders

Nasdaq delisting determination on June 22, 2026—shares suspended at open June 24, 2026, with appeal not providing a stay

Transition to Pink Limited Market will likely collapse daily trading volume as institutional and many retail brokers restrict trading in OTC stocks

Filing lacks any YoY/QoQ revenue, margin, or cash balance data—investors have zero visibility into operational health or turnaround timeline

No forward guidance or insider buying filed—signal that recovery is uncertain and management may not see value at current levels

After suspension, shares may be subject to 'piggyback' exemption rules under Rule 144, enabling cheap stock sales by affiliates after a cooling-off period

Even if the appeal succeeds, trading suspension has already occurred; relisting process could take weeks to months, during which price discovery in OTC could be adverse

Past violation was non-deliberate, but the company issued excess equity awards, indicating historical internal controls weakness—remediation appears complete but reputational risk lingers

Neither filing reported insider transactions, pledges, or changes in beneficial ownership—this is the norm for 8-Ks of this nature but limits the ability to gauge management conviction

Delisting triggers SEC scrutiny; if Nasdaq files Form 25 with the SEC, the company must comply with all periodic reporting to avoid further suspension from OTC markets

If the stock drops to distressed levels in the Pink Limited Market, risk-tolerant investors may find a deep-value entry point; watch for insider buying post-suspension as a catalyst

Nasdaq Listing and Hearing Review Council hearings can reverse delistings if the company submits a compliance plan—success rate for firms with credible path to compliance is ~15-25%—a binary optionality trade

Company plans to apply to OTCQB Market after suspension, which could restore some visibility and liquidity—if approved, shares may re-rate vs. Pink Limited

With the reprimand closed and corrective actions taken, the company now has a clean regulatory slate—no further Nasdaq action is pending, removing a key overhang

Freed from regulatory distraction, management can refocus on business execution; if YOY or QOQ growth data later emerges, the stock could re-rate favorably

Other Nasdaq-listed micro-caps with similar non-compliance issues may be trading at compressed multiples; use the DEVS delisting as a screen for short-term trading opportunities in beaten-down names

If the stock overshoots on the downside in the first few post-suspension days, a short-covering rally could occur—monitor short interest in the pre-suspension period

Filing shows no dividends, buybacks, or splits—capital is not being returned to shareholders, but also no dilution from buyback programs; neutral for cash preservation

In OTC markets, the stock could trade at a price approaching cash per share if disclosed in future filings—watch for a balance sheet update to establish intrinsic value floor

Both filings provide explicit deadlines and regulatory outcomes—unique clarity for investors to model binary events (suspension vs. reprimand) and plan entry/exit timing

Two micro-cap firms show opposite outcomes for similar regulatory breaches: TONX self-reported and survived (reprimand), while DEVS failed minimum price/net income tests and faces delisting. This highlights that Nasdaq severity depends on governance responsiveness and financial fundamentals

Both 8-Ks contain zero period-over-period comparisons (YoY/QoQ revenue, margins, or cash flows), leaving investors with no trend data to assess the financial health or trajectory of the companies during a critical regulatory event

Zero insider trades, pledges, or holdings changes were reported in either filing, suggesting management may be legally restricted from trading (blackout periods during material events) or chooses not to signal confidence

Neither filing contains any forward-looking statements, guidance, or forecasts—this absence amplifies uncertainty for DEVS investors facing suspension with no roadmap for compliance recovery

Both filings report no dividends, buybacks, or stock splits—shareholder return policies are non-existent, reflecting the micro-cap nature and cash conservation priorities of these issuers

The filings provide explicit event deadlines: DEVS suspension at Nasdaq open on June 24, 2026, with appeal timeline undefined; TONX has no further deadlines. This creates a clear trading timeline for risk management

Nasdaq suspension effective June 24, 2026, at open of business—watch for immediate price reaction in Pink Limited Market and volume surge [Date: June 24, 2026]

Company intends to file appeal; monitor for submission date and hearing timeline—if appeal is granted, could restore trading [Timeline: 30-60 days]

Watch for filing of OTCQB application—if approved, shares could regain some institutional eligibility and liquidity [Timeline: 2-4 weeks post-suspension]

Nasdaq may file Form 25 with the SEC to complete delisting—watch for SEC filing which triggers removal from SEC reporting obligations (if OTC doesn't continue) [Timeline: Within 10 days of suspension]

Watch for insider buys or sells in OTC market—any insider purchase could signal management's belief in recovery value [Ongoing]

TONX must file upcoming quarterly reports—watch for financial data that reveals whether the governance distraction impacted operational performance [Next filing by Aug 2026]

Post-delisting or reprimand, watch for shareholder class actions—DEVS is higher risk given material loss; any lawsuit filing could pressure stock further [Ongoing]